Lilly hunkers down for lean years with salary freeze

Eli Lilly ($LLY), languishing in the doldrums of its long-expected "Years YZ," has frozen the salaries of many of its staffers, including those of top management. As Pharmalot reports, the company disclosed in a recent Securities and Exchange Commission filing that employees in "most countries" around the globe "will not receive base pay increases in 2012." And for the third year in a row, CEO John Lechleiter (photo) has asked for no increase in salary or incentives for 2012.

The proxy statement attributes these moves to "the business challenges the company faces." These challenges aren't inconsiderable. Lilly's fourth quarter results showed that losing patent protection on its big-selling Zyprexa antipsychotic pill has hurt more than expected; sales already dropped by 44% to $749.6 million. Its Q4 profits fell by 27%, and earnings for 2012 are expected to take a big hit.

Lilly's patent-cliff "YZ" years were destined to be lean, but some R&D projects haven't panned out as hoped. The employees' hope for raises in 2013 could well depend on two ongoing trials of a potential Alzheimer's treatment. That data "is going to be the biggest thing they are going to report this year," Morningstar's Damien Conover told Bloomberg last week.

- see the SEC filing
- get the Pharmalot post

Suggested Articles

Merck’s Keytruda already boasts an OK in some esophageal cancer patients, but it’s looking to widen its reach in the tough-to-treat disease.

GI cancers are stubborn, as plenty of oncology drugmakers know. But BMS' Opdivo has broken through with two potentially practice-changing trials.

The custodial measure came after Chinese customs officials raided Genscript’s businesses for “suspected violations of import and export regulations.”